Taro Historical Income Statement
| TARO Stock | USD 42.51 0.12 0.28% |
Historical analysis of Taro Pharmaceutical income statement accounts such as EBIT of 19.4 M, Ebitda of 57.5 M, Cost Of Revenue of 367.8 M or Total Operating Expenses of 302.6 M can show how well Taro Pharmaceutical Industries performed in making a profits. Evaluating Taro Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Taro Pharmaceutical's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Taro Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Taro Pharmaceutical is a good buy for the upcoming year.
Taro |
About Taro Income Statement Analysis
Taro Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Taro Pharmaceutical shareholders. The income statement also shows Taro investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Taro Pharmaceutical Income Statement Chart
Taro Pharmaceutical Industries Income Statement is one of the three primary financial statements used for reporting Taro's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Taro Pharmaceutical revenue and expense. Taro Pharmaceutical Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Taro Pharmaceutical's Interest Expense is very stable compared to the past year. As of the 3rd of May 2024, Minority Interest is likely to grow to 0.00, while Total Revenue is likely to drop about 356.7 M. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Taro Pharmaceutical. It is also known as Taro Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Most accounts from Taro Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Taro Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Taro Pharmaceutical's Interest Expense is very stable compared to the past year. As of the 3rd of May 2024, Minority Interest is likely to grow to 0.00, while Total Revenue is likely to drop about 356.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 293.1M | 268.3M | 308.6M | 235.8M | Total Revenue | 561.3M | 573.0M | 658.9M | 356.7M |
Taro Pharmaceutical income statement Correlations
Click cells to compare fundamentals
Taro Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Taro Pharmaceutical income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Revenue | 644.8M | 549.0M | 561.3M | 573.0M | 658.9M | 356.7M | |
| Gross Profit | 399.7M | 296.7M | 293.1M | 268.3M | 308.6M | 235.8M | |
| Other Operating Expenses | 398.2M | 403.8M | 436.4M | 555.2M | 638.5M | 670.4M | |
| Operating Income | 246.5M | 704.4M | 184.4M | 17.7M | 20.4M | 19.4M | |
| Ebit | 246.5M | 704.4M | 184.4M | 17.7M | 20.4M | 19.4M | |
| Ebitda | 253.1M | 728.1M | 210.3M | 52.7M | 60.6M | 57.5M | |
| Cost Of Revenue | 245.0M | 252.3M | 268.2M | 304.6M | 350.3M | 367.8M | |
| Total Operating Expenses | 153.2M | 151.5M | 168.2M | 250.6M | 288.2M | 302.6M | |
| Income Before Tax | 298.0M | (391.1M) | 77.9M | 38.2M | 43.9M | 41.7M | |
| Total Other Income Expense Net | 51.5M | (1.1B) | (106.5M) | 20.5M | 18.4M | 19.4M | |
| Income Tax Expense | 53.5M | 9.7M | 19.6M | 12.8M | 14.7M | 24.0M | |
| Depreciation And Amortization | 6.5M | 23.7M | 25.9M | 34.9M | 40.2M | 42.2M | |
| Net Income | 244.2M | (400.7M) | 58.3M | 25.4M | 29.3M | 27.8M | |
| Research Development | 59.8M | 60.2M | 54.5M | 52.2M | 60.1M | 45.0M | |
| Interest Expense | 725K | 1.4M | 1.7M | 17.7M | 20.3M | 21.4M | |
| Selling General Administrative | 56.8M | 52.8M | 57.1M | 85.1M | 97.8M | 83.4M | |
| Net Income Applicable To Common Shares | 281.8M | 244.2M | (386.7M) | 58.3M | 67.0M | 63.7M | |
| Minority Interest | 5.2M | 5.6M | 5.9M | (8.2M) | (904K) | 0.0 | |
| Selling And Marketing Expenses | 36.7M | 38.5M | 56.6M | 113.3M | 130.3M | 136.8M | |
| Net Income From Continuing Ops | 244.6M | (400.7M) | 58.3M | 25.4M | 22.9M | 21.8M | |
| Tax Provision | 53.5M | 9.7M | 19.6M | 12.8M | 11.5M | 10.9M | |
| Interest Income | 22.7M | 20.2M | 8.2M | 20.9M | 18.8M | 14.6M | |
| Net Interest Income | 33.6M | 20.2M | 8.2M | 20.9M | 18.8M | 17.2M | |
| Reconciled Depreciation | 21.4M | 23.7M | 25.9M | 32.1M | 36.9M | 25.3M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Taro Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Taro Pharmaceutical's short interest history, or implied volatility extrapolated from Taro Pharmaceutical options trading.
Currently Active Assets on Macroaxis
When determining whether Taro Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taro Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taro Pharmaceutical Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taro Pharmaceutical Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Taro Stock analysis
When running Taro Pharmaceutical's price analysis, check to measure Taro Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taro Pharmaceutical is operating at the current time. Most of Taro Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Taro Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taro Pharmaceutical's price. Additionally, you may evaluate how the addition of Taro Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Taro Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taro Pharmaceutical. If investors know Taro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taro Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.782 | Earnings Share 1.22 | Revenue Per Share 16.252 | Quarterly Revenue Growth 0.129 | Return On Assets 0.0103 |
The market value of Taro Pharmaceutical is measured differently than its book value, which is the value of Taro that is recorded on the company's balance sheet. Investors also form their own opinion of Taro Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Taro Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taro Pharmaceutical's market value can be influenced by many factors that don't directly affect Taro Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taro Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taro Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taro Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.